DISEASE & TREATMENT SETTING

Myeloid Leukemia

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Myeloid Leukemia

Source population: Not part of this definition
Disease extent: Not part of this definition
Treatment line: Not part of this definition
Stage: Not part of this definition
Resectability: Not part of this definition

Biomarkers, prior therapy and derivation

molecular
prior therapy
derivation status: source-attested
derivation note: Added because the terminology and the registry both attest it: an NCIt neoplasm concept named by 4 acquired study condition(s). It is absent from the NCI treatment-topic directory, which is not an exhaustive cancer inventory.
source wording: Source null

Study evidence for this setting

Find a linked studyHow it was found

4 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

NCT00025662 · Registry condition search · Scope: narrower

Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS

5 outcome links · 1 safety-group records · 0 quality-of-life measures

→

NCT00967343 · Registry condition search · Scope: narrower

Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a

6 outcome links · 1 safety-group records · 1 quality-of-life measures

→

NCT01760655 · Registry condition search · Scope: narrower

Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies

6 outcome links · 1 safety-group records · 0 quality-of-life measures

→

NCT05282459 · Registry condition search · Scope: narrower

Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation

6 outcome links · 2 safety-group records · 0 quality-of-life measures

→

Indication-specific source history

Dated source events, not confirmation of current approval for every use of a drug.

2006-06-28 · Sprycel (dasatinib) · accelerated approval

release id: clinical-indications-draft-1
disease state id: ds-myeloid-leukemia
event id: fda-b649ecac7feccbaf
event date: 2006-06-28
event kind: accelerated-approval
drug or regimen: Sprycel (dasatinib)
source indication text: Chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib
match phrase: myeloid leukemia
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-197131992f87c2f02544
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2009-05-21 · Sprycel (dasatinib) · traditional approval

release id: clinical-indications-draft-1
disease state id: ds-myeloid-leukemia
event id: fda-b70c3effba5ac97e
event date: 2009-05-21
event kind: traditional-approval
drug or regimen: Sprycel (dasatinib)
source indication text: Chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib
match phrase: myeloid leukemia
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-197131992f87c2f02544
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2012-10-26 · Synribo (omacetaxine mepesuccinate) · accelerated approval

release id: clinical-indications-draft-1
disease state id: ds-myeloid-leukemia
event id: fda-c49c357d7d50d2da
event date: 2012-10-26
event kind: accelerated-approval
drug or regimen: Synribo (omacetaxine mepesuccinate)
source indication text: Adults with chronic or accelerated phase chronic myeloid leukemia with resistance or intolerance to 2 or more TKIs
match phrase: myeloid leukemia
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-2c3493f3e08411d42498
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2012-12-14 · Iclusig (ponatinib) · accelerated approval

release id: clinical-indications-draft-1
disease state id: ds-myeloid-leukemia
event id: fda-108760cbb44327a3
event date: 2012-12-14
event kind: accelerated-approval
drug or regimen: Iclusig (ponatinib)
source indication text: Adults with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia resistant or intolerant to TKI therapy or or Philadelphia chromosome positive acute lymphoblastic leukemia resistant or intolerant to prior TKI therapy
match phrase: myeloid leukemia
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-207b1271c5e76362e54d
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2014-02-10 · Synribo (omacetaxine mepesuccinate) · traditional approval

release id: clinical-indications-draft-1
disease state id: ds-myeloid-leukemia
event id: fda-224a19b0abbeb906
event date: 2014-02-10
event kind: traditional-approval
drug or regimen: Synribo (omacetaxine mepesuccinate)
source indication text: Adults with chronic or accelerated phase chronic myeloid leukemia with resistance or intolerance to 2 or more TKIs
match phrase: myeloid leukemia
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-2c3493f3e08411d42498
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2016-11-28 · Iclusig (ponatinib) · traditional approval

release id: clinical-indications-draft-1
disease state id: ds-myeloid-leukemia
event id: fda-89a66bf821990fc4
event date: 2016-11-28
event kind: traditional-approval
drug or regimen: Iclusig (ponatinib)
source indication text: Adults with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia resistant or intolerant to TKI therapy or or Philadelphia chromosome positive acute lymphoblastic leukemia resistant or intolerant to prior TKI therapy
match phrase: myeloid leukemia
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-207b1271c5e76362e54d
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2021-10-29 · Scemblix (asciminib) · accelerated approval

release id: clinical-indications-draft-1
disease state id: ds-myeloid-leukemia
event id: fda-26414c60d9721649
event date: 2021-10-29
event kind: accelerated-approval
drug or regimen: Scemblix (asciminib)
source indication text: Adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with 2 or more tyrosine kinase inhibitors (TKIs)
match phrase: myeloid leukemia
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-1b440f2c1ffd9a94caa9
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2022-10-12 · Scemblix (asciminib) · traditional approval

release id: clinical-indications-draft-1
disease state id: ds-myeloid-leukemia
event id: fda-1e4abc0adf4a73f8
event date: 2022-10-12
event kind: traditional-approval
drug or regimen: Scemblix (asciminib)
source indication text: Adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with 2 or more tyrosine kinase inhibitors (TKIs)
match phrase: myeloid leukemia
match status: candidate
status category: verified_clinical_benefit
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-1b440f2c1ffd9a94caa9
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2024-10-29 · Scemblix (asciminib) · accelerated approval

release id: clinical-indications-draft-1
disease state id: ds-myeloid-leukemia
event id: fda-1b7c1d04430bc918
event date: 2024-10-29
event kind: accelerated-approval
drug or regimen: Scemblix (asciminib)
source indication text: Treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).
match phrase: myeloid leukemia
match status: candidate
status category: ongoing
has date discrepancy: 0
source collection: fda-status-row
source key: fda-aa-f95ec17446197e3c8811
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2025-01-21 · treosulfan with fludarabine · approval notification

release id: clinical-indications-draft-1
disease state id: ds-myeloid-leukemia
event id: notice-dda9c909ee78c9da
event date: 2025-01-21
event kind: approval-notification
drug or regimen: treosulfan with fludarabine
source indication text: FDA approved treosulfan, an alkylating agent, with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients 1 year of age and older with acute myeloid leukemia or myelodysplastic syndrome .
match phrase: myeloid leukemia
match status: candidate
status category: Source null
has date discrepancy: 0
source collection: fda-approval-notice
source key: fda-eed3ef224dcd705a
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-treosulfan-fludarabine-preparative-regimen-allohsct-adult-and-pediatric-patients-aml-or
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2025-10-24 · revumenib · approval notification

release id: clinical-indications-draft-1
disease state id: ds-myeloid-leukemia
event id: notice-cc78578b202e4d53
event date: 2025-10-24
event kind: approval-notification
drug or regimen: revumenib
source indication text: FDA approved revumenib, a menin inhibitor, for relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation in adult and pediatric patients 1 year and older who have no satisfactory alternative treatment options.
match phrase: myeloid leukemia
match status: candidate
status category: Source null
has date discrepancy: 0
source collection: fda-approval-notice
source key: fda-61ed478e73d4f4a0
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-npm1-mutation
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2025-11-13 · ziftomenib · approval notification

release id: clinical-indications-draft-1
disease state id: ds-myeloid-leukemia
event id: notice-60632042036f2986
event date: 2025-11-13
event kind: approval-notification
drug or regimen: ziftomenib
source indication text: FDA approved ziftomenib, a menin inhibitor, for adults with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options.
match phrase: myeloid leukemia
match status: candidate
status category: Source null
has date discrepancy: 0
source collection: fda-approval-notice
source key: fda-970653d3c34dd8d5
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ziftomenib-relapsed-or-refractory-acute-myeloid-leukemia-npm1-mutation
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

2026-05-13 · oral combination of decitabine and cedazuridine tablets with venetoclax · approval notification

release id: clinical-indications-draft-1
disease state id: ds-myeloid-leukemia
event id: notice-c38a137a46e4fbf8
event date: 2026-05-13
event kind: approval-notification
drug or regimen: oral combination of decitabine and cedazuridine tablets with venetoclax
source indication text: FDA approved an oral combination of decitabine and cedazuridine tablets with venetoclax for the treatment of newly diagnosed acute myeloid leukemia in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.
match phrase: myeloid leukemia
match status: candidate
status category: Source null
has date discrepancy: 0
source collection: fda-approval-notice
source key: fda-990c1df07ad6d6a2
source url: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-oral-combination-decitabine-and-cedazuridine-tablets-venetoclax-newly-diagnosed-acute
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z

Original event source →

Source relationships and population-mapping limitations

bindings

release id
clinical-indications-draft-1
disease state id
ds-myeloid-leukemia
binding id
ncit-C3172
source collection
ncit-concept
source key
C3172
source excerpt
Source null
match status
exact
match note
Source null
recorded at
2026-09-10T00:00:00Z

mappings

Download this complete draft source relationship record →

Preserved source evidence · Not medical advice